As SGLT2 inhibitors dapagliflozin and empagliflozin improved liver enzymes and decreased liver fat [18] we analyzed also SGLT2 protein expression levels in our NAFLD group to elucidate the factors in the development of NASH. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.